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The International Life Science Institute
(ILSI) Health and Environmental Sciences
Institute (HESI) Committee on Application
of Genomics and Proteomics to Mechanism-
Based Risk Assessment was established to
advance the scientific basis for the develop-
ment and application of genomic and pro-
teomic methodologies to mechanism-based
risk assessment (Robinson et al. 2003). One
of the long-term objectives of the subcom-
mittee is to relate changes in gene and pro-
tein expression to other measures of toxicity.
Three toxicity working groups were formed
to assess the application of microarray tech-
nology to nephrotoxicity, hepatotoxicity, and
genotoxicity. The HESI Nephrotoxicity
Working Group conducted studies using
three nephrotoxicants—cisplatin, gentam-
icin, and puromycin—with different mecha-
nisms or target regions within the kidney
(Kramer et al. 2004). RNA was prepared at
one site and sent to other laboratories for
analysis on multiple microarray formats,
using individual and pooled animal samples. 
One of the primary objectives of
toxicogenomics is the development of gene
profiles characteristic of discrete toxicities
that are potentially measurable on any
well-designed and well-annotated microarray
platform (Hamadeh et al. 2002; Thomas
et al. 2001; Waring et al. 2001). The devel-
opment of toxicity profiles and specific gene
expression signatures requires the use of stan-
dardized conditions and the testing of a
number of drugs of distinct classes and
mechanisms, and therefore they are usually
developed on one platform technology.
Analytical validation of the veracity of gene
changes within a signature is usually
performed with an independent gene expres-
sion detection technology such as quantita-
tive reverse transcriptase–polymerase chain
reaction (qRT–PCR). An additional
approach to analytical gene profile validation
involves the detection of the identified gene
signature on microarray platforms that use
different types of probes to capture and
detect specific RNA transcripts within sam-
ples. Deposition in a public repository of
genomic data annotated with toxicity data
that was generated by the ILSI working
groups is one of the goals of this project
(Robinson et al. 2003). The potential to
mine gene expression data from diverse
sources that will eventually populate public
databases will be unrealized if gene profiles
of toxicity cannot be extrapolated from one
microarray platform to another. It is
encouraging that meta-analysis of microarray
data collected from different sources and on
different microarray formats has shown that
cohorts of genes dysregulated in prostate
cancer can be consistently identified across
data sets (Rhodes et al. 2002). However,
more effort must be devoted to evaluating
and improving data comparisons across plat-
forms, including verifying probe annota-
tions, gene family and splice variant analysis,
and comparability of statistical methods. 
In this article, we examine the cross-
platform and cross-experiment reproducibil-
ity of gene changes induced in rat kidney by
cisplatin treatment and identified as statisti-
cally significant on a custom cDNA array.
Of the studies performed by the HESI
Nephrotoxicity Working Group, the most
complete data set with the largest number of
microarray formats was available for the
study involving the antineoplastic agent and
regionally specific nephrotoxicant cisplatin.
RNA prepared from the kidneys of rats on
day 7 after a single injection of 5 mg/kg cis-
platin, a dose and time point coincident
with proximal tubule necrosis and regenera-
tion, was tested on three different cDNA-
spotted arrays (the NIEHS custom rat
cDNA array, the Incyte Rat Toxicology
GEM, and the PHASE-1 Rat 700 array)
and one high-density oligonucleotide array
(the Affymetrix RGU34A array). 
Materials and Methods
Animal studies. Sprague-Dawley rats
Crl:CD(SD)IGSBR VAF/Plus rats were
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Within the International Life Sciences Institute Committee on Genomics, a working group was
formed to focus on the application of microarray technology to preclinical assessments of drug-
induced nephrotoxicity. As part of this effort, Sprague-Dawley rats were treated with the nephro-
toxicant cisplatin at doses of 0.3–5 mg/kg over a 4- to 144-hr time course. RNA prepared from
these animals was run on a variety of microarray formats at multiple sites. A set of 93 differen-
tially expressed genes associated with cisplatin-induced renal injury was identified on the National
Institute of Environmental Health Sciences (NIEHS) custom cDNA microarray platform using
quadruplicate measurements of pooled animal RNA. The reproducibility of this profile of statisti-
cally significant gene changes on other platforms, in pooled and individual animal replicate sam-
ples, and in an independent study was investigated. A good correlation in response between
platforms was found among the 48 genes in the NIEHS data set that could be matched to probes
on the Affymetrix RGU34A array by UniGene identifier or sequence alignment. Similar results
were obtained with genes that could be linked between the NIEHS and Incyte or PHASE-1
arrays. The degree of renal damage induced by cisplatin in individual animals was commensurate
with the number of differentially expressed genes in this data set. These results suggest that gene
profiles linked to specific types of tissue injury or mechanisms of toxicity and identified in well-
performed replicated microarray experiments may be extrapolatable across platform technologies,
laboratories, and in-life studies. Key words: cisplatin, cross-platform, kidney, microarrays, nephro-
toxicity. Environ Health Perspect 112:488–494 (2004). doi:10.1289/txg.6676 available via
http://dx.doi.org/ [Online 15 January 2004]
purchased from Charles River Laboratories
(Raleigh, NC) and treated with cisplatin
(CAS no. 1566-27-1; Sigma Chemical Co.,
St. Louis, MO) or vehicle in two indepen-
dent studies. A preliminary study was con-
tracted by the National Institute of
Environmental Health Sciences (NIEHS)
at Integrated Laboratory Systems, Inc.
(Research Triangle Park, NC) using a sin-
gle dose of cisplatin to determine the feasi-
bility of and to direct the design of the
overall project. The single time point (on
day 7) and dose level (5 mg/kg) serve as a
biological replicate for the longest time
point of the high-dose group in the multi-
dose study. Serum chemistry parameters
were statistically evaluated by a pairwise
t-test following the conduct of a Bartlett’s
test for homogeneity of variance. A
Dunnett’s t test was used for those end
points for which the Bartlett’s test was not
significant (p-value > 0.05).
The multidose time course study was
performed at Pfizer’s Groton laboratories
(Groton, CT). Groups of five animals were
dosed once by ip injection with 0, 0.3, 1.0,
or 5.0 mg/kg cisplatin in saline. Animals
were sacrificed at 4, 24, 48, and 144 hr after
dosing. Kidneys were snap frozen in liquid
nitrogen for RNA isolation. Kidneys were
also sampled, fixed in 10% neutral buffered
formalin, and blocked in paraffin. Slides
from the kidney blocks were processed for
hematoxylin and eosin staining. 
RNA extraction. Homogenates were
prepared from entire kidneys and processed
using Qiagen RNeasy Maxi kits (Qiagen,
Valencia, CA). Purified total RNA was
quantitated by ultraviolet light spectropho-
tometric determination. Purity and quality
were confirmed on gels and an Agilent
2100 bioanalyzer (Agilent Technologies,
Palo Alto, CA). For pooled samples, equal
amounts of RNA were combined from
each animal in the treatment group. 
NIEHS custom cDNA array analysis.
RNA was labeled, hybridized to microarrays,
scanned, and images processed as described
(Amin et al. 2004). Briefly, total RNA
(35–75 µg) from control animals was labeled
with Cyanine 3 (Cy3)-conjugated dUTP
and total RNA from treated animals was
labeled with Cyanine 5 (Cy5)-conjugated
dUTP using SuperScript reverse transcriptase
(Invitrogen, Carlsbad, CA). The labeled
products from the control and treated animal
RNAs were mixed and hybridized to cDNA
microarrays in quadruplicate. The cDNA
arrays were scanned with an Axon scanner
(Axon Instruments, Foster City, CA) and
image analysis was conducted using the
ArraySuite, version 2.0, extensions of the
IPLab image processing software package
(Scanalytics, Fairfax, VA). Genes significantly
changed at 144 hr by 5 mg/kg cisplatin were
determined as outliers in at least three of
four fluor flip experiments with a 95% confi-
dence interval. The binomial probability of
chance occurrence at the ratio outlier fre-
quency queried was p < 0.000475. 
Affymetrix RGU34A array analysis.
Sample labeling, microarray hybridization,
washing, and scanning were performed
according to the manufacturer’s protocols
(Affymetrix, Inc., Santa Clara, CA). Briefly,
10 µg total RNA was reverse transcribed
using a T7-(dT)24 oligomer and SuperScript.
Biotin-labeled cRNA targets were prepared
from cDNA using T7 polymerase (Enzo
Diagnostics, Inc., Farmingdale, NY),
fragmented, and hybridized to the oligo-
nucleotide arrays. After staining with
R-phycoerythrin streptavidin (Molecular
Probes, Inc., Eugene, OR), arrays were
scanned on an Affymetrix GeneChip
Scanner 2500 at a photomultiplier tube
(PMT) setting of 1,500. The scans from
each array were globally scaled by setting the
average signal intensity to a target signal of
500. The data were analyzed using
Affymetrix Microarray Suite, version 5.0
(MAS 5.0). For samples from individual ani-
mals, pair-wise comparisons between each
treated animal and each of the five control
animals were performed; the signal log ratios
were averaged across comparisons; and
change calls were based on 60% or greater
agreement across the five comparisons.
PHASE-1 Rat 700 microarray analysis.
Sample labeling, microarray hybridizations,
and washes were performed according to
the protocol supplied by the manufacturer
(PHASE-1 Molecular Toxicology, Inc.,
Santa Fe, NM). Twenty µg of total RNA
was primed with oligo dT and labeled by
direct incorporation of either Cy3-dCTP
or Cy5-dCTP during reverse transcription.
cDNA from labeled treated and control
samples was purified on Wizard Series
9600 DNA purification resin (Promega
Corp., Madison, WI), combined, and
hybridized to the same microarray. Each
microarray was scanned using a ScanArray
4000 microarray scanner (PerkinElmer,
Inc., Wellesley, MA). PMT values were
adjusted to balance total fluorescence signal
between the two channels. QuantArray
software, version 2.0 (PerkinElmer, Inc.),
was used to quantitate the bound signal for
each spot on the microarray from the
ScanArray output TIFF file. Local back-
ground fluorescence was subtracted and the
resulting data Lowess normalized. The
calculated log2 ratios were averaged from
quadruplicate spots deposited for each
queried element on each array.
Incyte Rat Toxicology GEM analysis.
Transcription profiling using Incyte cDNA
gene expression microarrays (GEMs; Incyte
Corp., Palo Alto, CA) was performed
essentially as previously described (Schena
et al. 1996). Briefly, poly(A)+ RNA was
isolated using MicroPoly(A)Pure kits
(Ambion, Inc., Austin, TX). Aliquots of
200 ng mRNA were used to generate Cy3-
and Cy5-labeled cDNA probes using
GEMBrite probe labeling kits (Incyte
Corp.). Individual treated and control sam-
ple probes were labeled with Cy5, while a
pool of equal proportions of the control
group mRNAs was used to generate Cy3-
labeled cDNA probes. Probe hybridization
using Rat Toxicology GEMs was per-
formed at Incyte Corp. as previously
described (Schena et al. 1996). Each slide
was analyzed using an Incyte internal pro-
gram. Microarray hybridizations were eval-
uated with respect to five quality control
parameters, background correction, log
balance coefficient, absolute average signal,
differential expression ratio, and differen-
tial percentage. Signal intensities in the
Cy3 and Cy5 channels were normalized
using total average signal intensity in both
channels to generate a balance coefficient.
Elements with signal intensities P1 + P2
< 500, signal to background values P1STB
+ P2STB < 10, or area of coverage < 40%,
were recorded as absent values and were
omitted from further consideration. 
The complete data set is currently being
submitted to ArrayExpress (European
Bioinformatics Institute, Hinxton, UK;
http://www.ebi.ac.uk/arrayexpress) and will
be available for public download by the sec-
ond quarter of 2004. Accession numbers
referencing this data set will be available on
the HESI web site (http://hesi.ilsi.org/
index.cfm?pubentityid=120).
Real-time qPCR. Primers for heme
oxygenase-1 (Hmox1), clusterin (Clu),
osteopontin (Spp1), and solute carrier fam-
ily 15, member 2 (Slc15a2) were designed
using Primer Express software (Applied
Biosystems, Foster City, CA) and custom
made (Research Genetics, Huntsville, AL).
The primer sequences (5´ to 3´) were as
follows: Hmox1 forward CGTGCTCG
CATGAACACTCT, Hmox1 reverse
CGGTCTTAGCCTCTTCTGT, Clu for-
ward TGTGGACTGTTCGACCAACAA,
Clu reverse GAGGGAATGAAGCAGCT
CGTT, Spp1 forward CCAGCCAAGGA
CCAACTACAA, Spp1 reverse GCCAAA
CTCAGCCACTTTCAC, Slc15a2 forward
GCAATGGGAAGCAAGATGTACAG,
and Slc15a2 reverse GTGTTGTCGCT
TCGGAAGGT. Real-time PCR was per-
formed using the ABI Prism 7700 Sequence
Detection System (Applied Biosystems)
according to the manufacturer’s instructions.
The SYBR Green I labeling kit (Applied
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Biosystems) was used to detect double-
stranded DNA generated during PCR
amplification according to manufacturer’s
instructions. Reverse transcription and PCR
reactions were performed simultaneously in a
50-µL reaction containing 4 mM MgCl2,
0.8 mM of each dNTP, 100 ng total RNA,
0.4 µM reverse primer and 0.4 µM forward
primer, 0.4 U/µL Rnasin, 0.025 U/µL
AmpliTaq Gold DNA polymerase (Roche,
Basel, Switzerland) and 0.25 U/µL MuIV
reverse transcriptase (Roche). Amplification
reactions were carried out using the following
temperature profile: 48°C, 10 min; 95°C,
15 sec; 60°C, 1 min) for 40 cycles.
Fluorescence emission was detected for each
PCR cycle and the threshold cycle (CT) val-
ues were determined. The CT value was
defined as the actual PCR cycle when the flu-
orescence signal increased above the back-
ground threshold. Induction or repression of
a gene in a treated sample relative to control
was calculated as follows: fold increase/
decrease = 2 – [CT (exposed) – CT (control)].
Values were reported as an average of tripli-
cate analyses normalized to glyceraldehyde
phosphate dehydrogenase RNA levels. 
Results
Cross-platform comparisons. As part of the
studies conducted by the HESI Nephro-
toxicity Working Group, Sprague-Dawley
rats were injected with a single dose of cis-
platin (0, 0.3, 1, or 5 mg/kg) and sacrificed
after 4, 24, 48, or 144 hr. RNA prepared
from the kidneys of these animals was ana-
lyzed on several different microarray plat-
forms at different sites. The platforms
involved in this study include the NIEHS
custom array spotted with 7,000 cDNAs
and expressed sequence tags (ESTs), the
Affymetrix RGU34A array that contains
8,800 in situ synthesized oligonucleotide
probe sets, the Incyte Rat Toxicology GEM
that has 9,984 spotted cDNAs and ESTs,
and the PHASE-1 Rat Expression array
with 700 spotted cDNAs and ESTs. The
three cDNA platforms were all constructed
using PCR products of 500–2,000 nucleo-
tides in length amplified from libraries of
rat cDNA clones. The RGU34A array was
constructed using 16 pairs of perfect match
and single base-pair (bp) mismatched
oligonucleotides, each 25 bp in length, to
interrogate each transcript. 
A set of 93 genes was identified that
was significantly altered in the kidney after
exposure to a nephrotoxic dose of cisplatin
(5 mg/kg for 144 hr) on the NIEHS array
using four independent dye-swap measure-
ments of RNA pooled from individual ani-
mals (Amin et al. 2004). The pooled
high-dose cisplatin sample was analyzed at
different sites on the Affymetrix, Incyte,
and PHASE-1 platforms only in single chip
determinations. However, biological repli-
cates for this data point were run on all of
these three different platforms. Because
biological variability is thought to be
greater than technical variability for well-
performed microarray experiments (Yang
and Speed 2002), the data from the biolog-
ical replicates were used for the cross-plat-
form comparison. RNAs from the five rats
in the 144-hr high-dose cisplatin group
and the five rats in the 144-hr control
group were run on individual RGU34A
arrays in singlicate. On the Incyte and
PHASE-1 platforms, individual treated
animal samples were run in singlicate on
separate arrays, paired with pooled control
RNA labeled with a different fluor. It was
readily apparent from tallying the number
of gene changes above 2-fold on any of the
three platforms that the individual animals
did not respond homogeneously to cis-
platin. These observations were also
reflected in the traditional toxicologic end
points of histopathology and serum mark-
ers indicative of renal injury. Histopatho-
logic diagnosis revealed that three animals
(nos. 76, 77, and 78) had similar moderate
levels of single-cell necrosis and tubular
regeneration in the outer medulla of the
kidney, one animal (no. 79) had a mild
degree of injury, and one animal (no. 80)
had no visible kidney damage (Table 1).
The blood urea nitrogen (BUN) and serum
creatinine levels were significantly elevated
in animal nos. 76, 77, and 78 but were at
control levels in animal nos. 79 and 80.
Cross-platform comparisons can be
ascertained best when probe sequences on
the platforms used are fully and correctly
annotated. The most in-depth comparison of
probes between platforms was performed for
the NIEHS and Affymetrix RGU34A arrays,
for which the most complete publicly
available sequence information was available.
The NIEHS array is printed with PCR-
amplified sequences from sequence-verified
Research Genetics rat cDNA library clones
(Amin et al. 2004). The Affymetrix rat
genome U34A (RGU34A) oligonucleotide
array was designed to interrogate 7,000 full-
length sequences and about 1,000 EST clus-
ters from the UniGene (http://www.ncbi.
nih.gov/UniGene/) database (Build 34;
Affymetrix Inc. 2001). The probes of interest
were first cross-referenced between the two
platforms by UniGene identifier. Where
multiple probe sets on the RGU34A array
had the same UniGene identifier as a probe
of interest on the NIEHS array, the Probe
Match tool available on NetAffx (http://
www.affymetrix.com/analysis/inde.affx; Liu
et al. 2003) was used to determine which
RGU34A probe set had the maximal
sequence overlap with the spotted NIEHS
sequence. Although probe sequence overlap
was not necessary for good correlation of sig-
nal between platforms, it was used here to
develop the closest map between probe
sequences on the two platforms. Additionally,
the Probe Match tool was used to identify
Affymetrix probe sets that best corresponded
to NIEHS probes that had not been assigned
UniGene identifiers or had UniGene identi-
fiers that did not match the annotations
available for genes on the RGU34A array.
Finally, if there was poor agreement in per-
formance for probes matched across plat-
forms by UniGene identifier, the Probe
Match tool was used to query for better
sequence matches between NIEHS probes
and RGU34A probe sets. Probes of interest
on the NIEHS array were matched to
probes on the Incyte Rat Toxicology GEM
and PHASE-1 Rat 700 arrays by UniGene
identifier (Mattes 2004).
Forty-eight of the 93 differentially
expressed genes identified in the NIEHS
data set could be matched to probe sets on
the Affymetrix RGU34A array by UniGene
identifier or sequence match. An additional
34 genes in the NIEHS data set could be
matched to probe sets on the RGU34B and
C arrays, which were not used in this
study. For 11 of the 93 genes, either no
corresponding RGU34 probe set was
found or the sequence spotted on the
NIEHS array could not be confirmed by
sequence comparison against the National
Center for Biotechnology Information
(NCBI) nucleotide database using Basic
Local Alignment Search Tool (BLAST)
analysis (Altschul et al. 1997). Using the
annotation provided by the manufacturer
supplemented by BLAST analysis for a
subset of probes, 33 of the 93 genes in the
NIEHS data set were matched to probes
on the Incyte Rat Toxicology GEM.
Mini-Monograph | Thompson et al.
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Table 1. Variation in individual animal histopathology diagnosis and serum markers of nephrotoxicity. 
Individual animal no.
76 77 78 79 80
Single cell necrosis, outer medulla Moderate Moderate Moderate Mild None
Tubular degeneration Mild Mild Mild Mild None
Tubular regeneration Moderate Moderate Moderate Mild None
BUN (mg/dL)a 87 100 106 11 13
Serum creatinine (mg/dL)b 1.4 2.4 2.3 0.4 0.3
aControls (all time points): 13.05 ± 2.4 (average ± SD, n = 20). bControls (all time points): 0.28 ± 0.04 (average ± SD, n = 20).
Sixteen of the 93 could be matched to
probes on the PHASE-1 rat subarray. 
Gene expression data from each of the
three platforms for the three animals with
similar biological response to cisplatin were
averaged and compared with the response
determined using technical replicates of
pooled animal data on the NIEHS plat-
form (Tables 2 and 3). Among the
48 genes that could be linked between the
NIEHS and the RGU34A platform, a
good agreement in the direction, statistical
significance, and magnitude of change was
observed for the majority of the genes
(88%) in the data set. Ninety-four percent
of the 33 genes in the NIEHS data set
identified as present on the Incyte Rat
Toxicology GEM were also consistently
Mini-Monograph | Cross-platform study of nephrotoxicity
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Table 2. Genes associated with renal injury by cisplatin on multiple platforms. 
UniGene ID NIEHS IDa Gene symbolb Gene nameb NIEHSc Affymetrixd Calle Incyted PHASE-1d
Rn.1780 AA818413 Clu Clusterin 2.895 3.289 I 3.360 2.865
Rn.8871 AA964431 Spp1 Secreted phosphoprotein 1 2.064 2.173 I 2.599 1.312
Rn.2710 AA859385 Vim Vimentin 1.642 2.278 I 1.498 Absentf
Rn.90546 AA964578 Anxa2 Calpactin I heavy chain 1.328 2.167 I 2.140 2.005
Rn.2458 AA858888 Tubb5 Tubulin, beta 5 1.263 1.490 I 0.829 Absent
Rn.87063 AA955668 Gstp2 Glutathione S-transferase, pi 2 1.239 2.206 I 1.549 1.740
Rn.98846 AA925421 Fga Fibrinogen, alpha polypeptide 1.227 1.914 I 1.249 1.076
Rn.16933 NM053380 Slc34a2 Solute carrier family 34, member 2 1.118 Absent 0.607 Absent
Rn.5983 AA924288 Tmsb10 Thymosin beta 10 1.091 1.822 I 0.894 0.926
Rn.11303 NM130741 Lcn2 Lipocalin 2 1.057 3.943 I Absent Absent
Rn.5834 AA925280 Ccng1 Cyclin G1 0.978 2.605 I 1.355 1.505
Rn.24945 M31109 Udpgt UDP-Glucuronsyltransferase 2B3 0.926 0.721 I Absent Absent
L12458 Lyz Lysozyme 0.918 0.933 I Absent Absent
Rn.2521 NM031533 Ugt2b UDP-Glucuronosyltransferase 2 family, 0.895 0.503 I Absent Absent
polypeptide B
Rn.2605 AA819102 Tmsb4x Thymosin beta-4 0.895 0.885 I 1.191 Absent
Rn.4083 AA900235 S100a10 S-100 related protein, clone 42c 0.848 1.700 I 1.140 Absent
Rn.1119 NM022509 Smn Survival motor neuron 0.782 1.019 I Absent Absent
Rn.2379 AA874853 Mgp Matrix Gla protein 0.766 0.799 I 0.711 Absent
Rn.625 AA998734 Gstm2 Glutathione S-transferase, mu 2 0.740 1.259 I 1.144 0.039
Rn.764 AA859797 Lgals3 Lectin, galactose binding, soluble 3 0.678 2.060 I 1.305 0.328
Rn.2953 AA924727 Col1a1 Collagen type 1, alpha 1 0.614 0.569 I 0.598 Absent
Rn.3160 AA874884 Hmox1 Heme oxygenase 1 0.566 1.092 I Absent 0.455
Rn.3545 AI137902 Tgfb1i4 Transforming growth factor beta 1  0.526 0.671 I 0.737 Absent
induced transcript 4
Rn.10992 AA964628 G6pc Glucose-6-phosphatase –0.578 –1.370 D –1.270 Absent
Rn.26060 AA997886 Cyp2d18 Cytochrome P450 2D18 –0.578 –0.421 NC –0.692 –1.393
Rn.2178 AA819745 Ghr Growth hormone receptor –0.599 –1.340 D –0.857 Absent
Rn.2589 AA818579 Cdo1 Cysteine dioxygenase 1 –0.644 –1.627 D –0.939 Absent
Rn.103392 AA924904 EST –0.644 –1.373 D Absent Absent
Rn.11132 AA998088 Anpep Alanyl aminopeptidase –0.667 –1.798 D Absent Absent
Rn.1437 AA818706 Gc Group-specific component –0.713 –2.223 D Absent Absent
Rn.10417 AI029336 Hao3 Hydroxyacid oxidase 3 –0.737 –0.501 D –1.033 Absent
Rn.1874 AA818440 AGT2 Beta-alanine-pyruvate aminotransferase –0.737 –0.779 D –0.867 Absent
Rn.33890 AA819309 Gamt Guanidinoacetate methyltransferase –0.737 –1.265 D Absent Absent
Rn.89268 AA818855 Slc15a2 Solute carrier family 15, member 2 –0.737 –2.527 D –1.165 Absent
Rn.26369 AA819611 Igfbp3 Insulin-like growth factor binding protein 3 –0.761 –1.409 D –0.758 –0.905
Rn.54567 AA818636 Siat1 Sialyltransferase 1 –0.761 –1.429 D –1.061 Absent
Rn.9230 AA957263 EST, similar to connexin protein Cx26 –0.761 –1.203 D Absent Absent
Rn.11331 AA925291 Ngfg Nerve grown factor, gamma –0.837 –1.626 D –1.566 Absent
Rn.874 AA860013 Odc1 Ornithine decarboxylase 1 –0.837 –1.383 D Absent –1.176
Rn.11143 AI070884 Kap Kidney androgen-regulated protein –0.889 –1.806 D –2.100 Absent
Rn.1430 AA818680 Oat Ornithine aminotransferase –0.889 –1.930 D –1.177 –0.326
Rn.108214 AA858962 Rbp4 Retinol binding protein 4 –0.889 –2.220 D Absent –1.020
Rn.11133 AA998607 Kat2 Kynurenine aminotransferase 2 –0.971 –1.830 D –2.043 Absent
Rn.6075 AA901327 Egf Epidermal growth factor –1.218 –2.581 D –1.905 –1.905
Abbreviations: D, decrease; I, increase; NC, no change.
Values are fold inductions shown as log2 ratios. aUnderlined NIEHS ID is best BLAST match; nonunderlined NIEHS ID is spotted sequence. bAnnotated from the UniGene database
(http://www.ncbi.nih.gov/UniGene/). cAverage of four technical replicates of pooled RNA. dAverage of three biological replicates of individual animal RNAs. eCall by MAS 5.0 analysis.
f ”Absent” indicates that the probe sequence is not on the microarray.
Table 3. Genes associated with renal injury by cisplatin that were not confirmed on multiple platforms.
UniGene ID NIEHS IDa Gene symbolb Gene nameb NIEHSc Affymetrixd Calle Incyted PHASE-1d
Rn.3603 AA900551 Ephx1 Epoxide hydrolase 1 0.687 0.506 NC 0.479 Absentf
Rn.8707 AA955199 Gdf10 Prepro bone inducing protein 0.642 –0.198 NC Absent Absent
AA899443 EST, similar to mitochondrial cytochrome B –0.667 –0.291 NC Absent Absent
Rn.19270 AI059765 Anxa4 ZAP 36/annexin IV –0.713 0.622 I Absent Absent
Rn.10958 AI059692 Eef2k Eukaryotic elongation factor 2 kinase –0.761 –0.002 NC 0.163 Absent
Abbreviations: D, decrease; I, increase; NC, no change. 
Values are fold inductions shown as log2 ratios. aUnderlined NIEHS ID is best BLAST match; nonunderlined NIEHS ID is spotted sequence. bAnnotated from the UniGene database.
cAverage of four technical replicates of pooled RNA. dAverage of three biological replicates of individual animal RNAs. eCall by MAS 5.0 analysis. f”Absent” indicates that the probe
sequence is not on the microarray. 
changed > 1.5-fold among the biological
replicates assayed on that platform.
Seventy-five percent of the 16 genes in the
NIEHS data set that matched to the
PHASE-1 Rat 700 array showed a repro-
ducible change > 1.5-fold among the bio-
logical replicates. Five of the genes that
were significantly changed on the NIEHS
platform in the kidney samples lacked con-
cordance of response with the matched
probes on other platforms (Table 3).
Correct annotation of the five probe
sequences on the NIEHS platform was
reconfirmed by BLAST analysis. For 3 of
the 5 probes, there was complete sequence
overlap between the 16 probe pairs in the
most homologous Affymetrix probeset
identified and the cDNA sequence. For 2
probes, there was partial overlap between
the cDNA and Affymetrix probe pair
sequences. Discordant outcomes between
platforms may result from cross-hybridiza-
tion on the cDNA platforms to nontarget
sequences, differential detection of alter-
nate splice variants by probes from the
same UniGene cluster, misannotation of
probes on arrays, mistakes in probe place-
ment on arrays, or large differences in
hybridization affinity between probe
sequences from the same UniGene cluster. 
A strong concordance was observed
between the degree of renal injury induced
by cisplatin in individual animals, as deter-
mined by traditional toxicological end
points and the strength of correlation of the
corresponding gene expression results
between platforms. RNA assayed on the
RGU34A platform from the three animals
(nos. 76–78) that incurred a similar, moder-
ate level of renal injury from cisplatin
showed the highest concordance of response
with the results on the NIEHS array deter-
mined using RNA pooled from the five
individual animals in this group (Table 4).
Of the 48 genes in the data set cross-
matched between the NIEHS and RGU34A
platforms, 41–42 genes from each of ani-
mals nos. 76, 77, and 78 were assigned
change calls using MAS 5.0 analysis of
RGU34A arrays that agreed with the results
from quadruplicate measurements of pooled
RNA on the NIEHS array (Figure 1). The
Pearson correlation coefficients between the
individual animal data determined on
oligonucleotide arrays and the pooled data
determined on cDNA arrays showed rela-
tively good correlation and close agreement
between biological replicates (Table 4).
Kidney RNA from animal no. 79, which
had a milder response to cisplatin, displayed
fewer significant changes among the genes
indicative of proximal tubular injury. The
Pearson correlation coefficient for the com-
parison between the log2 ratio data for ani-
mal no. 79 and the pool assayed on the
NIEHS platform was lower (0.655) and
only 20 of the 48 genes had change calls in
agreement in this comparison. In the kidney
RNA from animal no. 80, which showed no
histopathology response to cisplatin, only 3
of the 48 genes in the data set altered after
cisplatin treatment were significantly
changed from control levels and the Pearson
correlation coefficient was –0.141 between
the log2 ratio data for animal no. 80 and the
NIEHS pool. Similar correlation between
gene expression and degree of renal injury
for the five individual animals treated with
5 mg/kg cisplatin for 144 hr were seen using
the Incyte Rat Toxicology GEM and
PHASE-1 Rat Array (Table 4). 
Individual versus pooled animal results.
The presence of one apparent nonresponder
and one weakly responding animal among
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NIEHS
Pool 76 77 78 79 80
Affymetrix
PoolNIEHS ID Affymetrix ID Matched by Gene symbol
AA900235 J03627_at UniGene S100a10
AA818413 M64733mRNA_s_at UniGene Clu
AA964431 M14656_at UniGene Spp1
AA859385 X62952_at UniGene Vim
AA964578 L13039_s_at UniGene Anxa2
AA925421 M35601_at UniGene Fga
AA924288 M58404_at UniGene Tmbs10
AA925280 X70871_at UniGene Ccng1
L12458 rc_AA892775_at Locuslink Lyz
AA859797 J02962_at UniGene Lgals3
AA924727 U75405UTR#1_f_at UniGene Col1a1
AA955668 X02904cds_s_at UniGene Gstp2
NM_130741 rc_AA9466503_at UniGene Lcn2
AA819102 M34043_at UniGene Tmsb4x
AA998734 J02810mRNA_s_at UniGene Gstm1
M31109 M31109_f_at UniGene Udpgt
AI137902 L25785_at UniGene Tgfb1i4
NM_022509 AF044910_at UniGene Smn
AA874853 rc_AI012030_at UniGene Mgp
AA874884 rc_AI179610_at UniGene Hmox1
AA858888 AB011679_at UniGene Tubb5
NM_031533 X03478cds_f_at UniGene Ugt2b
AA900551 M26125_at UniGene Ephx1
AA955199 D49494UTR#1_g_at UniGene Gdf10
AI059766 rc_AI171167_at UniGene Anxa4
AI059692 X96426_at UniGene Eef2k
AA997886 rc_AA997886_s_at UniGene Cyp2d18
AA899443 rc_AI103396_g_at Probe Match EST
AA818440 AB002584_at UniGene AGT2
AA819611 M31837_at UniGene Igfbp3
AA818706 M12450_at UniGene Gc
AA819745 Z83757mRNA_at UniGene Ghr
AA964628 L37333_s_at UniGene G6pc
AA818579 rc_AA942685_at UniGene Cdo1
AA924904 AB000717exons#1-8_s_at Probe Match EST
AA819309 J03588_at UniGene Gamt
AA818636 M83143_g_at UniGene Siat1
AA957263 X51615_g_at Probe Match EST
AA860013 J04792_at UniGene Odc1
AA818680 rc_AA893325_at UniGene Oat
AA998607 Z50144_at UniGene Kat2
AA901327 U04842_at UniGene Egf
AI029336 rc_AI232087_at UniGene Hao3
AI070884 U25808_at UniGene Kap
AA998088 M25073_at UniGene Anpep
AA925291 J00758_s_at Probe Match Ngfg
AA818855 rc_AI232096_at UniGene Sic15a2
AA858962 M10934_s_at Probe Match Rbp4
Individual animal number
Figure 1. Comparison of gene expression results for the intersection of cisplatin-altered genes on the
NIEHS cDNA and Affymetrix RGU34A platforms. The direction of the statistically significant change in
pooled or individual animal analyses is indicated by color. Blue represents decreased expression; red
represents increased expression; black indicates not changed, as determined by MAS 5.0 analysis on
Affymetrix arrays.
Table 4. Correlation between cisplatin-altered gene changes in pooled animal samples on the NIEHS
platform and individual animal samples for probes common to other individual platforms.
Platforms compared Individual animal number
with NIEHS array 76 77 78 79 80 Pool No. of genesa
Affymetrix RGU34A 0.896b 0.881 0.874 0.655 –0.141 0.781 48
Incyte Rat Toxicology GEM 0.942 0.940 0.941 0.830 –0.378 NA 33
PHASE-1 Rat Array 0.948 0.930 0.912 0.803 –0.333 0.972 16
NA, not available. aNumber of genes in comparison. bAll values are Pearson correlation coefficients. 
five animals in a treatment group might be
expected to dilute the signal of genes
changed by renal injury in pooled samples.
This result was observed on the RGU34A
array (Figure 1, Table 4). Specifically, a
lower Pearson correlation coefficient and
fewer MAS 5.0 change calls were seen with
pooled RNA than with samples from the
individual animals displaying the full
response to cisplatin (32 vs. ~ 41). Although
a similar loss of signal was not seen with
the PHASE-1 platform, this could be due
to greater technical variation. The individ-
ual animal samples were hybridized on a
different day than the pooled sample, and
it has been observed that dye effects seen
with this platform are most consistent
within hybridization batch (Rosenzweig
et al. 2004). Although the cisplatin-
induced data set was determined on the
NIEHS platform using pooled animal
samples, the statistical power added by the
use of four replicates might compensate
for some loss of signal due to pooling.
However, if a uniform response is not seen
among animals within an individual treat-
ment group as was observed in this study,
pooling may attenuate measurable gene
expression changes and conceal small but
biologically relevant changes. 
Verification by qRT–PCR of differen-
tially expressed genes. The changes in
expression assayed on multiple microarray
formats in kidneys with proximal tubule
damage were further verified for 4 genes by
qRT–PCR assay (Table 5). In the pooled
animal sample, heme oxygenase-1 (Hmox1)
was induced almost 8-fold (log2 ratio of 3)
in the qRT–PCR assay but 2-fold or less
on the oligonucleotide- and cDNA-based
platforms. In contrast, Clu was induced
about 3-fold in the qRT–PCR assay and 6-
to 10-fold on microarrays. Spp1 and
Slc15a2 genes were induced or repressed to
similar extents in the qRT–PCR assay
and on all platforms assayed in this study
where present. 
Repeatability of in vivo studies. The
cross-study applicability of the set of gene
markers of cisplatin-induced injury was
examined using data from the preliminary
study conducted by the Nephrotoxicity
Working Group at an independent site from
the multidose study, including RNA prepa-
ration. For the preliminary study, six ani-
mals per treatment group received a single
injection of saline or 5 mg/kg cisplatin and
were sacrificed 144 hr later. All animals in
the group displayed significantly lower body
weights and liver weights at sacrifice, but
only slight elevations were observed in BUN
(28 mg/dL ± 7 mg/dL, mean ± SD, in
treated vs. 17 mg/dL ± 1 mg/dL in controls;
Cochran-Cox t-test pairwise p-value of 0.01)
and serum creatinine (0.6 mg/dL ±
0.06 mg/dL in treated vs. 0.25 mg/dL ±
0.08 mg/dL in controls; Dunnett’s test pair-
wise p-value < 0.05). The RNA from the
animals was pooled within the treated and
control groups and tested on PHASE-1
arrays on six replicate arrays with flipped
fluor labeling. Among the 16 genes in the
NIEHS set of cisplatin-altered genes that
match to probes on the PHASE-1 platform,
a similar trend in gene expression change
was observed between replicate experiments
on the same array and across arrays
(Figure 2), even though serum markers of
renal dysfunction were altered to different
extents in the two studies. One gene
(Gstm2) that showed a significant change
only on the NIEHS platform and not on
the PHASE-1 platform in either replicate
study was discovered on closer inspection to
have been originally misannotated on the
NIEHS array. Recent BLAST analysis of the
spotted NIEHS sequence at this location
revealed that the closest sequence match for
this probe was with Gstm1, not Gstm2.
Probes correctly annnotated and matched
between the NIEHS and Phase-1 arrays
might be anticipated to perform similarly
with the same samples if differences in probe
labeling, hybridization, scanning, and data
processing do not mask the true gene
expression changes within the samples
because both arrays were constructed from
the same library of rat cDNA clones. 
Discussion 
In this study we examined the ability of
different microarray formats to identify
gene expression changes in kidneys of rats
treated with cisplatin. A set of differentially
expressed genes that were significantly
changed was developed from four replicate
determinations on a custom cDNA array.
We found that a significant subset of the
genes in this set could be identified as dif-
ferentially expressed on each of the other
platforms, transcending specific target cap-
ture technologies and providing additional
validation to their inclusion in the profile.
These data also suggest that the same biol-
ogy can be captured and reported, inde-
pendent of gene coverage, by different
array formats when gene profiles are devel-
oped that are linked to defined toxicities. 
Many of the 43 genes in the platform-
independent gene profile have known
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Table 5. Verification by qRT–PCR of cisplatin-altered gene changes measured on multiple microarray formats.
Gene symbol qRT–PCR NIEHS Affymetrix Incytea PHASE-1
Hmox1 2.74 0.56 1.09 Absentb 0.65
Clu 1.72 2.90 2.59 2.43 3.26
Spp1 2.38 2.06 2.11 1.95 1.84
Slc15a2 –1.00 –0.74 –1.14 –0.83 Absent
Values are log2 fold inductions for pooled animal samples. aAverage of five biological replicates (not determined for
pooled animal samples). b“Absent” indicates that the probe sequence is not on the microarray.
Figure 2. Comparison of average log2 ratios between independent in vivo experiments. Average log2 ratios
for the 16 genes significantly altered in rat kidney by 5 mg/kg cisplatin on the NIEHS custom cDNA array
and cross-matched to the PHASE-1 Rat Toxicology array are shown for pooled animal samples from the
same study on the NIEHS array and PHASE-1 array and for an independent study on the PHASE-1 array.
Genes are designated by locus symbol.
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structural or functional ontologies that are
consistent with the biology associated with
cisplatin nephrotoxicity. Genes associated
with damage to proximal tubules, tissue
remodeling, and regeneration are repre-
sented in this set. Genes involved in
cytoskeletal structure and function (Vim,
Tubb5, Tmsb10, Tmsb4x, Anxa2), in cell
adhesion (Spp1, Col1a1, Clu, Lgals3), and
detoxification enzymes (Gstm2, Gstp2) are
upregulated following cisplatin-induced
injury. Genes downregulated by cisplatin
include those that localize to the proximal
tubules (Odc1, Oat, G6pc, Kap) and those
that encode growth factors or their binding
proteins (Egf, Ngfg, Igfbp3, Ghr).
Further global analyses of gene expression
changes associated with different types of
nephrotoxicity will be necessary to define
which genes in this set are hallmarks of spe-
cific mechanisms of injury and which are
more general markers of renal damage,
immune cell invasion, or tissue remodeling.
Subsets of the genes identified as platform-
independent markers of cisplatin-induced
renal damage in this study have been
observed in other global analyses of differen-
tially expressed genes after renal damage.
Significant changes in the expression of Clu,
Tmsb10, Ccng1, Igfbp3, and Egf were
observed in kidney RNA from male Sprague-
Dawley rats that received daily injections of
1 mg/kg cisplatin for 7 days using PHASE-1
Rat 250 microarrays (Huang et al. 2001).
Upregulation of Tubb5, Col1a1, Gst, Lgals3,
and Anxa2 and downregulation of Igfbp3 and
Egf were also observed in ischemia-induced
acute renal failure in mice on Affymetrix
Murine U74A arrays (Yoshida et al. 2002).
Calcium oxalate nephrolithiasis induced
Tmsb4x, Col1a1, Spp1, and Tgfb1i4 expres-
sion in rat kidney analyzed on a custom
cDNA microarray (Katsuma et al. 2002).
Analysis of the same sample on different
microarray formats can provide an alternate
approach for confirming gene expression
changes. Discordant results between plat-
forms may identify examples of incorrect
annotation or cross-hybridization to non-
target gene sequences. Other potential
sources of variability such as differences in
RNA extraction or other processing meth-
ods were not addressed in this study. Earlier
cross-platform studies that compared the
correlation between all statistically changed
genes that can be mapped between different
platforms have shown either poor correla-
tion or disparities in sensitivity between
platforms (Kuo et al. 2002; Li et al. 2002).
The higher degree of correlation between
platforms seen in this study may be due to
the use of a data set composed of statistically
significant gene changes from individual
animal replicates that were phenotypically
anchored to histopathology and to the use
of sequence alignment to match probes
between different platforms. As more experi-
ence is gained with multiplatform analysis,
probes will be identified that are able to
detect particular gene transcripts with higher
fidelity, enhancing our capability for opti-
mizing measurements of gene expression
changes on a genome scale. The current
state of knowledge about the rat transcrip-
tome, gene families, and splice variants hin-
ders complete and accurate cross-annotation
of the targets detected by probes on different
platforms. Continued probing of sequence
validation based on cross-platform analyses
should help improve the overall quality of
microarray gene expression data. 
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